The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 06, 2015
Filed:
Aug. 31, 2012
Applicants:
Reiko Yasuda, Kanagawa, JP;
Yuzuru Eto, Kanagawa, JP;
Yoshiro Kitahara, Kawasaki, JP;
Inventors:
Assignee:
AJINOMOTO CO., INC., Tokyo, JP;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/535 (2006.01); A01N 57/00 (2006.01); A61K 31/66 (2006.01); C07C 309/51 (2006.01); A61K 31/167 (2006.01); A61K 31/17 (2006.01); A61K 31/198 (2006.01); A61K 31/27 (2006.01); A61K 31/4045 (2006.01); A61K 31/417 (2006.01); A61K 31/4245 (2006.01); A61K 31/4402 (2006.01); A61K 31/5377 (2006.01); C07C 275/42 (2006.01); C07C 311/32 (2006.01); C07C 311/51 (2006.01); C07C 333/08 (2006.01); C07C 335/16 (2006.01); C07D 209/14 (2006.01); C07D 213/74 (2006.01); C07D 233/61 (2006.01); C07D 271/10 (2006.01); C07D 295/16 (2006.01); C07D 413/04 (2006.01); C07C 53/18 (2006.01); C07D 213/75 (2006.01); C07D 295/192 (2006.01); C07D 417/04 (2006.01);
U.S. Cl.
CPC ...
C07C 309/51 (2013.01); A61K 31/167 (2013.01); A61K 31/17 (2013.01); A61K 31/198 (2013.01); A61K 31/27 (2013.01); A61K 31/4045 (2013.01); A61K 31/417 (2013.01); A61K 31/4245 (2013.01); A61K 31/4402 (2013.01); A61K 31/5377 (2013.01); C07C 53/18 (2013.01); C07C 275/42 (2013.01); C07C 311/32 (2013.01); C07C 311/51 (2013.01); C07C 333/08 (2013.01); C07C 335/16 (2013.01); C07D 209/14 (2013.01); C07D 213/74 (2013.01); C07D 213/75 (2013.01); C07D 233/61 (2013.01); C07D 271/10 (2013.01); C07D 295/16 (2013.01); C07D 295/192 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01); C07C 2101/14 (2013.01); C07C 2101/18 (2013.01);
Abstract
An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).